 | Up a level |
Journal Article
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Sehouli, J., Mahner, S., Neunhoeffer, T., Harter, P., de Gregorio, N., Fridrich, C., Markmann, S., Richter, R., Potenberg, J., Lorenz, R., Schmidt, M., Doering, G., Belau, A., Lueck, H. J., Chekerov, R., du Bois, A. and Hilpert, F. (2016). Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial. Int. J. Gynecol. Cancer, 26. S. 2 - 4. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438